Sermorelin sequence: stimulating growth hormone
Here the rise has a clear clinical destination: height in children with growth hormone deficiency. The sequence is short, the history is specific and the adult reputation reaches much further.
GHRH(1–29) and sermorelin acetate
Sermorelin corresponds to the first 29 amino acids of human growth-hormone-releasing hormone, with an amidated end. GHRH(1–29), GRF(1–29) and GRF(1–29)NH2 are names used for this active fragment. Its acetate name describes the salt form. The review of GHRH biology places it within the wider family of release-hormone analogues.
The sequence retains the full release activity of GHRH at its receptor. Sermorelin stimulates the pituitary to produce and release growth hormone, while feedback through somatostatin and IGF-1 can still restrain secretion. The peptide itself breaks down within minutes.
There is something pleasingly economical about that fragment. A shorter sequence can retain the relevant signal. CJC-1295 modifies the same starting region to resist breakdown and, with DAC, remain attached to albumin. The shared starting point helps explain their relationship; it also makes careless borrowing of one drug’s results particularly easy.
Children’s first year of growth
A multicentre trial in prepubertal children with growth hormone deficiency measured height growth during sermorelin treatment. First-year height velocity increased from about 4.1 to roughly 7–8 centimeters per year, without excessive IGF-1 generation.
That is an outcome with a reason to want it: children whose growth had been limited by deficient hormone production grew faster. The blood response had a clinical destination. The people, problem and measured improvement fit together. The specificity gives that claim credibility for me.
The finding stays with those children. It establishes no adult improvement in energy, muscle strength or memory. For me, the height result is strongest when it stays attached to the children whose growth was measured.
Adult claims and tesamorelin
The argument for adult sermorelin often starts with its preserved feedback. A 2006 editorial about adult-onset growth hormone insufficiency favoured that physiological rationale. It was an opinion piece, with no head-to-head trial demonstrating better health than direct growth hormone treatment. A 2008 editorial on secretagogues and aging judged the evidence insufficient.
The feedback argument has my sympathy. The sympathy stops short of assigning it an unmeasured health benefit. Large, long-term trials have not established sermorelin’s proposed wellness or anti-aging effects in healthy adults.
The cognition paper sometimes drawn into this discussion used tesamorelin. In that trial of 152 older adults, including 66 with mild cognitive impairment, treatment lasted 20 weeks, cognition improved and IGF-1 rose by 117% within the physiological range. The drug name matters as much as the attractive result. That study supplies no direct sermorelin memory finding.
Sermorelin safety questions
Growth hormone can oppose insulin’s action. The review of secretagogues identifies glucose elevation and reduced insulin sensitivity as class concerns, and asks for longer safety data. Growth hormone and IGF-1 also have growth-promoting actions, leaving a mechanistic concern about existing tumours. Preserved feedback has not settled long-term cancer risk from adult sermorelin use.
Reports of deeper sleep, more energy and gradual fat loss are anecdotal accounts, not clinical evidence. The same body of personal accounts includes redness or itching around injection sites, headache, flushing, nausea, puffiness, drowsiness, hunger and occasional tingling or higher sugar readings. The products and concurrent diet or exercise changes were unverified.
The mixed sleep reports sustain my curiosity, particularly because good and bad experiences coexist. They do not establish a dependable time to benefit. The questions page separates a reported sensation from the outcomes that these trials actually measured.
Approval history and present status
A sermorelin acetate medicine had FDA approval for children with growth hormone deficiency and short stature. It left the US market in 2008 for commercial reasons; FDA did not find that safety or effectiveness problems caused withdrawal. No FDA-approved sermorelin medicine is marketed now.
Sermorelin is treated as a Category 1 bulk substance under FDA’s interim Section 503A policy, whose final guidance was issued in January 2025. FDA does not intend enforcement action against compounding that meets the policy’s conditions. Compounded preparations remain unapproved, and a prescription alone does not establish that all conditions are met.
That history differs from the unapproved development of ipamorelin and CJC-1295. It also differs from an approval for adult aging claims. WADA prohibits sermorelin in sport. The comparison of the four research records preserves these distinctions without turning the old paediatric result into an adult treatment recommendation.